EE197 The Impact of Funding Tocilizumab for the Inpatient Treatment of COVID-19 in the United States: A Distributional Cost-Effectiveness Analysis

Abstract

Authors

KL Rosettie J Best S Kowal

Full Text Cite This Article
Back to Volume 27, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×